6606 Stock Overview
New Horizon Health Limited, an investment holding company, engages in the research and development of screening products for colorectal, cervical, and other types of cancer in the People’s Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
New Horizon Health Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$14.14 |
| 52 Week High | HK$32.55 |
| 52 Week Low | HK$13.76 |
| Beta | 1.3 |
| 1 Month Change | -23.98% |
| 3 Month Change | -25.42% |
| 1 Year Change | -47.14% |
| 3 Year Change | -78.67% |
| 5 Year Change | n/a |
| Change since IPO | -83.17% |
Recent News & Updates
New Horizon Health Limited (HKG:6606) Stocks Shoot Up 29% But Its P/S Still Looks Reasonable
Mar 04
Should You Investigate New Horizon Health Limited (HKG:6606) At HK$18.38?
Jan 30Recent updates
New Horizon Health Limited (HKG:6606) Stocks Shoot Up 29% But Its P/S Still Looks Reasonable
Mar 04Should You Investigate New Horizon Health Limited (HKG:6606) At HK$18.38?
Jan 30Should You Think About Buying New Horizon Health Limited (HKG:6606) Now?
Sep 28New Horizon Health (HKG:6606) Is Posting Healthy Earnings, But It Is Not All Good News
Sep 28Benign Growth For New Horizon Health Limited (HKG:6606) Underpins Stock's 26% Plummet
Aug 02New Forecasts: Here's What Analysts Think The Future Holds For New Horizon Health Limited (HKG:6606)
Jul 14News Flash: Analysts Just Made A Substantial Upgrade To Their New Horizon Health Limited (HKG:6606) Forecasts
Mar 19Growth Investors: Industry Analysts Just Upgraded Their New Horizon Health Limited (HKG:6606) Revenue Forecasts By 26%
Jan 13News Flash: Analysts Just Made A Captivating Upgrade To Their New Horizon Health Limited (HKG:6606) Forecasts
Mar 23Need To Know: Analysts Are Much More Bullish On New Horizon Health Limited (HKG:6606) Revenues
Jan 19Shareholder Returns
| 6606 | HK Healthcare | HK Market | |
|---|---|---|---|
| 7D | 0% | 6.4% | 3.6% |
| 1Y | -47.1% | -28.6% | -10.1% |
Return vs Industry: 6606 underperformed the Hong Kong Healthcare industry which returned -29.2% over the past year.
Return vs Market: 6606 underperformed the Hong Kong Market which returned -10.9% over the past year.
Price Volatility
| 6606 volatility | |
|---|---|
| 6606 Average Weekly Movement | 10.4% |
| Healthcare Industry Average Movement | 6.5% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in HK Market | 14.6% |
| 10% least volatile stocks in HK Market | 3.7% |
Stable Share Price: 6606's share price has been volatile over the past 3 months.
Volatility Over Time: 6606's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 1,041 | Yeqing Zhu | ir.newhorizonbio.com |
New Horizon Health Limited, an investment holding company, engages in the research and development of screening products for colorectal, cervical, and other types of cancer in the People’s Republic of China. Its products include ColoClear, an early screening products for colon cancer; Pupu Tube, a fecal occult blood self test product; and UU Tube, a helicobacter pylori self-test products. The company is also involved in the research and development of medical diagnostic technology; provision of technical services, transfers, and consultation; and medical services, as well as financing services; manufacturing and sales of medical and laboratory equipment, and fecal occult blood test kits; and technological import and export activities.
New Horizon Health Limited Fundamentals Summary
| 6606 fundamental statistics | |
|---|---|
| Market cap | HK$6.34b |
| Earnings (TTM) | HK$120.72m |
| Revenue (TTM) | HK$1.47b |
52.6x
P/E Ratio4.3x
P/S RatioIs 6606 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6606 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.36b |
| Cost of Revenue | CN¥153.40m |
| Gross Profit | CN¥1.21b |
| Other Expenses | CN¥1.10b |
| Earnings | CN¥111.70m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.25 |
| Gross Margin | 88.74% |
| Net Profit Margin | 8.20% |
| Debt/Equity Ratio | 12.7% |
How did 6606 perform over the long term?
See historical performance and comparison